pe a Search Results


91
Carolina Biological little marvel pea seeds
Little Marvel Pea Seeds, supplied by Carolina Biological, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+a/bio_rxiv__2021__11__26__470156-191-0-9?v=Carolina+Biological
Average 91 stars, based on 1 article reviews
little marvel pea seeds - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology anti general pea 15
Anti General Pea 15, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+a/us12286439-314-27-58?v=Santa+Cruz+Biotechnology
Average 93 stars, based on 1 article reviews
anti general pea 15 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
DSMZ pathotype p 2 lentil isolate l1
Pathotype P 2 Lentil Isolate L1, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+a/pm41902230-227-54-49?v=DSMZ
Average 93 stars, based on 1 article reviews
pathotype p 2 lentil isolate l1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

90
OriGene human pea 15 cdna
Human Pea 15 Cdna, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+a/pmc03354053-411-13-18?v=OriGene
Average 90 stars, based on 1 article reviews
human pea 15 cdna - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
R&D Systems polyclonal sheep ped antibody
Polyclonal Sheep Ped Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+a/pmc05682677-138-14-19?v=R%26D+Systems
Average 90 stars, based on 1 article reviews
polyclonal sheep ped antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

93
ATCC mb 2216 agar
Mb 2216 Agar, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+a/pmc08776838-57-13-2?v=ATCC
Average 93 stars, based on 1 article reviews
mb 2216 agar - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
ChromaDex bisdemethoxycurcumin
Bisdemethoxycurcumin, supplied by ChromaDex, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+a/pmc02921884-45-5-9?v=ChromaDex
Average 93 stars, based on 1 article reviews
bisdemethoxycurcumin - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

90
ATCC a1s 2215
A1s 2215, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+a/pmc07273844-22-2-16?v=ATCC
Average 90 stars, based on 1 article reviews
a1s 2215 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

pemv  (DSMZ)
91
DSMZ pemv
Pemv, supplied by DSMZ, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+a/10__1186_slash_s42483___023___00169___x-154-6-20?v=DSMZ
Average 91 stars, based on 1 article reviews
pemv - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier

90
Addgene inc fluorescent protein egfp degradation reporter
(A) Lollipop plot of LZTR1 mutations identified in blood of subjects with clonal hematopoiesis (7). (B) Representative histograms of GFP in 293T cells encoding RIT1 fused to <t>eGFP</t> and empty vector (Vector), wild-type (WT) LZTR1, or any of four CH-associated LZTR1 mutations. % of eGFP+ cells indicated. Red dotted line indicates the cutoff for GFP+. (C) Quantification of data from (B). Mean ± SD. *p<0.05, **p<0.01, ***p<0.001. (D) Schema of allele for Lztr1 constitutive or conditional gene disruption. (E) Western blots of Lztr1 and RAS GTPases in E14.5 fetal liver cells from Lztr1 WT or knockout embryos. (F) Immunofluorescence images of Lztr1 wild-type or null embryos for cleaved caspase 3 (green), Ter119 (red), and DAPI (blue) in whole mount (top; WT bar: 100μm; KO bar: 50μm) or focused on fetal livers (bottom; bar, 20μm). (G) Schema of experiments evaluating effects of Lztr1 deletion on fetal hematopoietic cells in vitro and in vivo. (H) Colony number in methylcellulose replating assays using 20×103 fetal liver hematopoietic cells from Lztr1+/+, Lztr1+/−, and Lztr1−/− fetus. Mean ± SD. n=3. ***p<0.001, ****p<0.0001. (I) % of CD45.2+ cells in peripheral blood of CD45.1+ recipient mice following primary and secondary competitive transplantation. n=5–10. **p<0.01, ****p<0.0001. (J) Box-and-whisker plots of the percentage (%) of total CD45.2+ cells in the bone marrow. n=5. **p<0.01. (K) % of CD45.2+ hematopoietic stem and progenitors following 16 weeks of competitive transplantation (as shown in the schema in Fig. 1G). n=5. *p<0.05, **p<0.01, ****p<0.0001. (L) Kaplan-Meier curve of primary and secondary transplant recipient mice. Pie chart indicates number and proportion of analyzed mice developing lethal hematopoietic malignancies across both primary and secondary transplantation. Lztr1+/+ primary (1o) recipient mice n=7, Lztr1−/− primary (1o) recipient mice n=7, Lztr1−/− secondary (2o) recipient mice n=30. *p<0.05, ****p<0.0001. (M) Peripheral blood counts of CD45.1+ recipient mice transplanted with CD45.2+ Lztr1+/+ or Lztr1−/− fetal liver cells. n=6–10. **p<0.01. (N) Flow cytometric analysis of live, CD45.2+ Lztr1−/− cells from secondary transplant recipient mice developing myeloid neoplasms or B-cell acute lymphoblastic leukemias.
Fluorescent Protein Egfp Degradation Reporter, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+a/pmc09533010-465-16-21?v=Addgene+inc
Average 90 stars, based on 1 article reviews
fluorescent protein egfp degradation reporter - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
ATCC snap pea cultivar designated sl3118
(A) Lollipop plot of LZTR1 mutations identified in blood of subjects with clonal hematopoiesis (7). (B) Representative histograms of GFP in 293T cells encoding RIT1 fused to <t>eGFP</t> and empty vector (Vector), wild-type (WT) LZTR1, or any of four CH-associated LZTR1 mutations. % of eGFP+ cells indicated. Red dotted line indicates the cutoff for GFP+. (C) Quantification of data from (B). Mean ± SD. *p<0.05, **p<0.01, ***p<0.001. (D) Schema of allele for Lztr1 constitutive or conditional gene disruption. (E) Western blots of Lztr1 and RAS GTPases in E14.5 fetal liver cells from Lztr1 WT or knockout embryos. (F) Immunofluorescence images of Lztr1 wild-type or null embryos for cleaved caspase 3 (green), Ter119 (red), and DAPI (blue) in whole mount (top; WT bar: 100μm; KO bar: 50μm) or focused on fetal livers (bottom; bar, 20μm). (G) Schema of experiments evaluating effects of Lztr1 deletion on fetal hematopoietic cells in vitro and in vivo. (H) Colony number in methylcellulose replating assays using 20×103 fetal liver hematopoietic cells from Lztr1+/+, Lztr1+/−, and Lztr1−/− fetus. Mean ± SD. n=3. ***p<0.001, ****p<0.0001. (I) % of CD45.2+ cells in peripheral blood of CD45.1+ recipient mice following primary and secondary competitive transplantation. n=5–10. **p<0.01, ****p<0.0001. (J) Box-and-whisker plots of the percentage (%) of total CD45.2+ cells in the bone marrow. n=5. **p<0.01. (K) % of CD45.2+ hematopoietic stem and progenitors following 16 weeks of competitive transplantation (as shown in the schema in Fig. 1G). n=5. *p<0.05, **p<0.01, ****p<0.0001. (L) Kaplan-Meier curve of primary and secondary transplant recipient mice. Pie chart indicates number and proportion of analyzed mice developing lethal hematopoietic malignancies across both primary and secondary transplantation. Lztr1+/+ primary (1o) recipient mice n=7, Lztr1−/− primary (1o) recipient mice n=7, Lztr1−/− secondary (2o) recipient mice n=30. *p<0.05, ****p<0.0001. (M) Peripheral blood counts of CD45.1+ recipient mice transplanted with CD45.2+ Lztr1+/+ or Lztr1−/− fetal liver cells. n=6–10. **p<0.01. (N) Flow cytometric analysis of live, CD45.2+ Lztr1−/− cells from secondary transplant recipient mice developing myeloid neoplasms or B-cell acute lymphoblastic leukemias.
Snap Pea Cultivar Designated Sl3118, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+a/us08420894-503-4-14?v=ATCC
Average 90 stars, based on 1 article reviews
snap pea cultivar designated sl3118 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

93
Proteintech pea
(A) Lollipop plot of LZTR1 mutations identified in blood of subjects with clonal hematopoiesis (7). (B) Representative histograms of GFP in 293T cells encoding RIT1 fused to <t>eGFP</t> and empty vector (Vector), wild-type (WT) LZTR1, or any of four CH-associated LZTR1 mutations. % of eGFP+ cells indicated. Red dotted line indicates the cutoff for GFP+. (C) Quantification of data from (B). Mean ± SD. *p<0.05, **p<0.01, ***p<0.001. (D) Schema of allele for Lztr1 constitutive or conditional gene disruption. (E) Western blots of Lztr1 and RAS GTPases in E14.5 fetal liver cells from Lztr1 WT or knockout embryos. (F) Immunofluorescence images of Lztr1 wild-type or null embryos for cleaved caspase 3 (green), Ter119 (red), and DAPI (blue) in whole mount (top; WT bar: 100μm; KO bar: 50μm) or focused on fetal livers (bottom; bar, 20μm). (G) Schema of experiments evaluating effects of Lztr1 deletion on fetal hematopoietic cells in vitro and in vivo. (H) Colony number in methylcellulose replating assays using 20×103 fetal liver hematopoietic cells from Lztr1+/+, Lztr1+/−, and Lztr1−/− fetus. Mean ± SD. n=3. ***p<0.001, ****p<0.0001. (I) % of CD45.2+ cells in peripheral blood of CD45.1+ recipient mice following primary and secondary competitive transplantation. n=5–10. **p<0.01, ****p<0.0001. (J) Box-and-whisker plots of the percentage (%) of total CD45.2+ cells in the bone marrow. n=5. **p<0.01. (K) % of CD45.2+ hematopoietic stem and progenitors following 16 weeks of competitive transplantation (as shown in the schema in Fig. 1G). n=5. *p<0.05, **p<0.01, ****p<0.0001. (L) Kaplan-Meier curve of primary and secondary transplant recipient mice. Pie chart indicates number and proportion of analyzed mice developing lethal hematopoietic malignancies across both primary and secondary transplantation. Lztr1+/+ primary (1o) recipient mice n=7, Lztr1−/− primary (1o) recipient mice n=7, Lztr1−/− secondary (2o) recipient mice n=30. *p<0.05, ****p<0.0001. (M) Peripheral blood counts of CD45.1+ recipient mice transplanted with CD45.2+ Lztr1+/+ or Lztr1−/− fetal liver cells. n=6–10. **p<0.01. (N) Flow cytometric analysis of live, CD45.2+ Lztr1−/− cells from secondary transplant recipient mice developing myeloid neoplasms or B-cell acute lymphoblastic leukemias.
Pea, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+a/pmc08494857-291-0-20?v=Proteintech
Average 93 stars, based on 1 article reviews
pea - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


(A) Lollipop plot of LZTR1 mutations identified in blood of subjects with clonal hematopoiesis (7). (B) Representative histograms of GFP in 293T cells encoding RIT1 fused to eGFP and empty vector (Vector), wild-type (WT) LZTR1, or any of four CH-associated LZTR1 mutations. % of eGFP+ cells indicated. Red dotted line indicates the cutoff for GFP+. (C) Quantification of data from (B). Mean ± SD. *p<0.05, **p<0.01, ***p<0.001. (D) Schema of allele for Lztr1 constitutive or conditional gene disruption. (E) Western blots of Lztr1 and RAS GTPases in E14.5 fetal liver cells from Lztr1 WT or knockout embryos. (F) Immunofluorescence images of Lztr1 wild-type or null embryos for cleaved caspase 3 (green), Ter119 (red), and DAPI (blue) in whole mount (top; WT bar: 100μm; KO bar: 50μm) or focused on fetal livers (bottom; bar, 20μm). (G) Schema of experiments evaluating effects of Lztr1 deletion on fetal hematopoietic cells in vitro and in vivo. (H) Colony number in methylcellulose replating assays using 20×103 fetal liver hematopoietic cells from Lztr1+/+, Lztr1+/−, and Lztr1−/− fetus. Mean ± SD. n=3. ***p<0.001, ****p<0.0001. (I) % of CD45.2+ cells in peripheral blood of CD45.1+ recipient mice following primary and secondary competitive transplantation. n=5–10. **p<0.01, ****p<0.0001. (J) Box-and-whisker plots of the percentage (%) of total CD45.2+ cells in the bone marrow. n=5. **p<0.01. (K) % of CD45.2+ hematopoietic stem and progenitors following 16 weeks of competitive transplantation (as shown in the schema in Fig. 1G). n=5. *p<0.05, **p<0.01, ****p<0.0001. (L) Kaplan-Meier curve of primary and secondary transplant recipient mice. Pie chart indicates number and proportion of analyzed mice developing lethal hematopoietic malignancies across both primary and secondary transplantation. Lztr1+/+ primary (1o) recipient mice n=7, Lztr1−/− primary (1o) recipient mice n=7, Lztr1−/− secondary (2o) recipient mice n=30. *p<0.05, ****p<0.0001. (M) Peripheral blood counts of CD45.1+ recipient mice transplanted with CD45.2+ Lztr1+/+ or Lztr1−/− fetal liver cells. n=6–10. **p<0.01. (N) Flow cytometric analysis of live, CD45.2+ Lztr1−/− cells from secondary transplant recipient mice developing myeloid neoplasms or B-cell acute lymphoblastic leukemias.

Journal: Cancer discovery

Article Title: Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation

doi: 10.1158/2159-8290.CD-21-1631

Figure Lengend Snippet: (A) Lollipop plot of LZTR1 mutations identified in blood of subjects with clonal hematopoiesis (7). (B) Representative histograms of GFP in 293T cells encoding RIT1 fused to eGFP and empty vector (Vector), wild-type (WT) LZTR1, or any of four CH-associated LZTR1 mutations. % of eGFP+ cells indicated. Red dotted line indicates the cutoff for GFP+. (C) Quantification of data from (B). Mean ± SD. *p<0.05, **p<0.01, ***p<0.001. (D) Schema of allele for Lztr1 constitutive or conditional gene disruption. (E) Western blots of Lztr1 and RAS GTPases in E14.5 fetal liver cells from Lztr1 WT or knockout embryos. (F) Immunofluorescence images of Lztr1 wild-type or null embryos for cleaved caspase 3 (green), Ter119 (red), and DAPI (blue) in whole mount (top; WT bar: 100μm; KO bar: 50μm) or focused on fetal livers (bottom; bar, 20μm). (G) Schema of experiments evaluating effects of Lztr1 deletion on fetal hematopoietic cells in vitro and in vivo. (H) Colony number in methylcellulose replating assays using 20×103 fetal liver hematopoietic cells from Lztr1+/+, Lztr1+/−, and Lztr1−/− fetus. Mean ± SD. n=3. ***p<0.001, ****p<0.0001. (I) % of CD45.2+ cells in peripheral blood of CD45.1+ recipient mice following primary and secondary competitive transplantation. n=5–10. **p<0.01, ****p<0.0001. (J) Box-and-whisker plots of the percentage (%) of total CD45.2+ cells in the bone marrow. n=5. **p<0.01. (K) % of CD45.2+ hematopoietic stem and progenitors following 16 weeks of competitive transplantation (as shown in the schema in Fig. 1G). n=5. *p<0.05, **p<0.01, ****p<0.0001. (L) Kaplan-Meier curve of primary and secondary transplant recipient mice. Pie chart indicates number and proportion of analyzed mice developing lethal hematopoietic malignancies across both primary and secondary transplantation. Lztr1+/+ primary (1o) recipient mice n=7, Lztr1−/− primary (1o) recipient mice n=7, Lztr1−/− secondary (2o) recipient mice n=30. *p<0.05, ****p<0.0001. (M) Peripheral blood counts of CD45.1+ recipient mice transplanted with CD45.2+ Lztr1+/+ or Lztr1−/− fetal liver cells. n=6–10. **p<0.01. (N) Flow cytometric analysis of live, CD45.2+ Lztr1−/− cells from secondary transplant recipient mice developing myeloid neoplasms or B-cell acute lymphoblastic leukemias.

Article Snippet: RIT1 degradation reporter assay RIT1 and RIT1 M90I mutant cDNAs were cloned into an enhanced green fluorescent protein (eGFP) degradation reporter (Addgene #74459).

Techniques: Plasmid Preparation, Disruption, Western Blot, Knock-Out, Immunofluorescence, In Vitro, In Vivo, Transplantation Assay, Whisker Assay

(A) Histogram of number of patients with RIT1 mutations based on myeloid malignancy diagnosis. Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndromes; MDS/MPN: myelodysplastic syndromes/myeloproliferative neoplasms; MF: myelofibrosis; No Dx: no diagnosis. (B) Diagram of location of RIT1 mutations identified. (C) Variant allele frequency (VAF) of mutations in RAS GTPases or regulators of RAS GTP abundance relative to mutations in transcriptional modifiers in myeloid leukemia patients. (D) Fish tail representation plots of VAFs of mutations across serial genomic analysis of three RIT1 mutant patients. (E) Western blot of LZTR1 and RIT1 following cycloheximide (CHX) treatment of TF-1 cells with or without LZTR1 deletion. (F) Representative histograms of GFP in cells encoding wild-type or mutant RIT1 fused to eGFP along with empty vector (EV), wild-type LZTR1, or mutant LZTR1. % of eGFP+ cells indicated. Red dotted line indicates the cutoff for GFP+. (G) Levels of phosphorylated and total MEK1/2 and ERK1/2 as well as RIT1 in TF-1 cells with LZTR1 deletion or expression of empty vector RIT1 wild-type (WT) or mutant cDNAs. (H) Western blot of pERK and total ERK levels in 293T cells transfected with increasing amounts of FLAG-RIT1 wild-type (WT) and mutant cDNAs.

Journal: Cancer discovery

Article Title: Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation

doi: 10.1158/2159-8290.CD-21-1631

Figure Lengend Snippet: (A) Histogram of number of patients with RIT1 mutations based on myeloid malignancy diagnosis. Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndromes; MDS/MPN: myelodysplastic syndromes/myeloproliferative neoplasms; MF: myelofibrosis; No Dx: no diagnosis. (B) Diagram of location of RIT1 mutations identified. (C) Variant allele frequency (VAF) of mutations in RAS GTPases or regulators of RAS GTP abundance relative to mutations in transcriptional modifiers in myeloid leukemia patients. (D) Fish tail representation plots of VAFs of mutations across serial genomic analysis of three RIT1 mutant patients. (E) Western blot of LZTR1 and RIT1 following cycloheximide (CHX) treatment of TF-1 cells with or without LZTR1 deletion. (F) Representative histograms of GFP in cells encoding wild-type or mutant RIT1 fused to eGFP along with empty vector (EV), wild-type LZTR1, or mutant LZTR1. % of eGFP+ cells indicated. Red dotted line indicates the cutoff for GFP+. (G) Levels of phosphorylated and total MEK1/2 and ERK1/2 as well as RIT1 in TF-1 cells with LZTR1 deletion or expression of empty vector RIT1 wild-type (WT) or mutant cDNAs. (H) Western blot of pERK and total ERK levels in 293T cells transfected with increasing amounts of FLAG-RIT1 wild-type (WT) and mutant cDNAs.

Article Snippet: RIT1 degradation reporter assay RIT1 and RIT1 M90I mutant cDNAs were cloned into an enhanced green fluorescent protein (eGFP) degradation reporter (Addgene #74459).

Techniques: Biomarker Discovery, Variant Assay, Mutagenesis, Western Blot, Plasmid Preparation, Expressing, Transfection